Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
34169203
Public Release Type:
Journal
Publication Year: 2021
DOI:
https://doi.org/10.1016/j.ekir.2021.03.892
Authors:
Beck Laurence H., Berasi Stephen P., Copley J. Brian, Gorman Donal, Levy Daniel I., Lim Chay Ngee, Henderson Joel M., Salant David J., Lu Weining
Request IDs:
21411
Studies:
Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis: Phase II Clinical Trial
Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and a histologic pattern of glomerular lesions of diverse etiology that share features including glomerular scarring and podocyte foot process effacement. Roundabout guidance receptor 2 (ROBO2)/slit guidance ligand 2 (SLIT2) signaling destabilizes the slit diaphragm and reduces podocyte adhesion to the glomerular basement membrane (GBM). Preclinical studies suggest that inhibition of glomerular ROBO2/SLIT2 signaling can stabilize podocyte adhesion and reduce proteinuria. This clinical trial evaluates the preliminary efficacy and safety of ROBO2/SLIT2 inhibition with the ROBO2 fusion protein PF-06730512 in patients with FSGS.
